


Age-related macular degeneration

The case for increased funding for medical research

The number of people with late AMD in the UK is increasing



2015 - 600K



2050 - 1.3M

The % of people with late AMD increases with age

≥ 65 Years 4.9%
≥ 80 Years 13.2%

Our population is ageing

60-74 Years **2014** 9.7M **2024** 11.1M
75+ Years **2014** 5.2M **2024** 7M

So the incidences of AMD will keep rising unless we do something about it

Cost of AMD from 2010 to 2020 will be more than £16.4bn of which:

Healthcare treatment £2.9bn
Personal and social costs £12.5bn

There is vast research potential



UK produces world leading research. Significant advances are being made in areas including stem cells and gene therapy

Too little is being spent on research

- 2014 £3.01bn of public funding invested in medical research
- 2013 - 2014 more than £400m spent on cancer research
- 2014 only £22.7m spent on eye research, of which £6m on AMD
- AMD represents 49% of registered sight loss but attracts only 27% of eye research funding
- 2014, UK sight loss charities had joint income of £774m of which just £1.5m funded AMD research

AMD is a devastating condition

88% of people said they would least like to lose their sight in a recent survey



The advanced stage of disease equates to a 60% drop in quality of life

Change the future medical research is costly but you can make a difference

- £15 liquid to grow cells in for clinical testing
- £300 an antibody for use in clinical research
- £100,000 funds electroretinography to study early AMD
- £40 sterile microscope slides
- £1,000 store, maintain and transport donor eye tissue for 1 year
- £75,000 buys scanning laser microscope for clinical research

It is time for **the research community**, **research funders** and the **third sector** to join together to beat AMD - visit www.macularsociety.org

